David Caleb Kombo

US Patent:

20110257168, Oct 20, 2011

Filed:

Jul 1, 2009

Appl. No.:

13/055085

Inventors:

Srinivasa R. Akireddy - Winston-Salem NC, US
Scott R. Breining - Winston-Salem NC, US
Nikolai Fedorov - Winston-Salem NC, US
David Kombo - Winston-Salem NC, US
Anatoly A. Mazurov - Greensboro NC, US
Lan Miao - Advance NC, US
Srinivasa V. Murthy - Lewisville NC, US
Todd Showalter - Clemmons NC, US
Yunde Xiao - Clemmons NC, US
Daniel Yohannes - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/5383
A61P 29/00
C07D 498/04

US Classification:

5142305, 544 74

Abstract:

The present invention relates to compounds of formula (I) that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

US Patent:

20110262407, Oct 27, 2011

Filed:

Nov 9, 2009

Appl. No.:

13/124829

Inventors:

Merouane Bencherif - Winston-Salem NC, US
Kristen Jordan - Clemmons NC, US
Terry Hauser - Winston-Salem NC, US
Steven M. Toler - Winston-Salem NC, US
Sharon Rae Letchworth - Kernersville NC, US
David C. Kombo - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 35/12
A61P 37/06
A61P 35/00
A61P 9/00
A61P 17/02
A61P 27/16
A61P 27/02
A61P 3/10
A61P 19/00
A61K 31/439
A61P 17/14

US Classification:

424 937, 514305

Abstract:

The present invention includes methods, uses, and selective alpha7 nAChR ligands for treating or preventing disease and disorders in which stimulation of neurogenesis is ameliorative; namely, wherein the recruitment of neurogenesis is therapeutic.

US Patent:

20110263629, Oct 27, 2011

Filed:

Sep 2, 2009

Appl. No.:

13/061972

Inventors:

Jon-Paul Strachan - Burlington NC, US
Balwinder Singh Bhatti - Winston-Salem NC, US
Anatoly Mazurov - Greensboro NC, US
Jozef Klucik - Marietta GA, US
Yunde Xiao - Clemmons NC, US
Philip S. Hammond - Pinnacle NC, US
David Kombo - Winston-Salem NC, US
Lan Miao - Advance NC, US
Jason Daniel Speake - Winston-Salem NC, US
Daniel Yohannes - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

A61K 31/439
A61P 25/00
A61P 25/28
A61P 25/18
A61P 3/04
A61P 3/00
A61P 37/06
A61P 25/30
A61P 25/04
C07D 471/08
A61P 29/00

US Classification:

514278, 546113, 546 15, 514300

Abstract:

The present invention relates to compounds that bind to and modulate the activity of neuronal nicotinic acetylcholine receptors, to processes for preparing these compounds, to pharmaceutical compositions containing these compounds, and to methods of using these compounds for treating a wide variety of conditions and disorders, including those associated with dysfunction of the central nervous system (CNS).

US Patent:

20130308840, Nov 21, 2013

Filed:

Apr 22, 2013

Appl. No.:

13/867432

Inventors:

Joseph Chewning - Winston-Salem NC, US
David Kombo - Winston-Salem NC, US
Beverly Ludwick - Winston-Salem NC, US

Assignee:

Targacept, Inc. - Winston-Salem NC

International Classification:

G06F 17/30

US Classification:

382128

Abstract:

A method of obtaining chemical or molecular compound information from a document is provided. The method includes applying optical structure recognition to a document and extracting compound structure information from data obtained by applying the optical structure recognition. The method includes applying a text search module to a main body of the document and metadata of the document and extracting one or more chemical names from data obtained by applying the text search module to the main body and to the metadata. The method includes storing, in a database, an identifier, the compound structure information, and the one or more chemical names, wherein at least one method operation is executed through a processor.

US Patent:

20100144700, Jun 10, 2010

Filed:

Mar 12, 2008

Appl. No.:

12/530997

Inventors:

Philip S. Hammond - Pinnacle NC, US
Anatoly A. Mazurov - Greensboro NC, US
Lan Miao - Advance NC, US
Balwinder Singh Bhatti - Winston-Salem NC, US
Jon-Paul Strachan - Burlington NC, US
V. Srinivasa Murthy - Winston-Salem NC, US
David C. Kombo - Winston-Salem NC, US
Srinivisa Rao Akireddy - Winston-Salem NC, US

Assignee:

TARGACEPT, INC. - Winston-Salem NC

International Classification:

A61K 31/439
C07D 471/08
C07D 487/04
C07D 471/04
A61K 31/407
A61K 31/422
A61K 31/437
A61K 31/4353
A61P 25/00
A61P 25/28
A61P 25/18

US Classification:

51421016, 546113, 548453, 548248, 514300, 514414, 514378

Abstract:

A compound of Formula 1: A-C(O)-Cy, wherein A is a diazabicyclic core, containing 7, 8, or 9 ring atoms, and selected from the following: 2,6-diazabicyclo[3.2.0]heptane; 3,6-diazabicyclo[3.ZO]heptane; 2,7-diazabicyclo[4.2.0]octane; 3,7-diazabicyclo[4.2.0]octane; 3,8-diazabicyclo[4.2.0]octane; 2,7-diazabicyclo[3.3.0]octane; 2,7-diazbicyclo[4.3.0]nonane; 2,8-diazbicyclo[4.3.0]nonane; 3,7-diazabicyclo[4.3.0]nonane; 3,8-diazabicyclo[4.3.0]nonane; 3,9-diazabicyclo[4.3.0]nonane; 2,6-diazabicyclo[3.2.1]octane; 3,6-diazabicyclo[3.2.1]octane; wherein the diazabicycle is attached as a radical to the depicted carbonyl via either one of the two ring nitrogen atoms, such that the carbonyl forms an amide bond with the ring nitrogen; Cy is a heteroaryl group; The compounds exhibit selectivity for, and bind with high affinity to, neuronal nicotinic receptors of the α402 subtype in the central nervous system (CNS). The compounds and compositions can be used to treat and/or prevent a wide variety of conditions or disorders, particularly CNS disorders. The compounds are believed to: (i) alter the number of nicotinic cholinergic receptors of the brain of the patient, (ii) exhibit neuroprotective effects, and (iii) when employed in effective amounts, not result in appreciable adverse side effects, namely side effects such as significant Increases in blood pressure and heart rate, significant negative effects upon the gastrointestinal tract, and significant effects upon skeletal muscle.

US Patent:

20220227739, Jul 21, 2022

Filed:

Aug 25, 2021

Appl. No.:

17/411682

Inventors:

- Boston MA, US
Cecilia M. Bastos - South Grafton MA, US
Daniel Parks - Pepperell MA, US
David Kombo - Lexington MA, US

International Classification:

C07D 405/04
C07D 405/14
C07D 413/14
C07D 401/04
C07D 409/04
C07D 409/14
C07D 413/04
C07D 417/04
C07D 471/04
C07D 487/04
C07D 493/08
A61K 45/06
A61P 11/00

Abstract:

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

US Patent:

20200385365, Dec 10, 2020

Filed:

Dec 17, 2019

Appl. No.:

16/716765

Inventors:

- Boston MA, US
Cecilia M. Bastos - South Grafton MA, US
Daniel Parks - Pepperell MA, US
David Kombo - Lexington MA, US

International Classification:

C07D 405/04
C07D 405/14
C07D 413/14
C07D 401/04
C07D 409/04
C07D 409/14
C07D 413/04
C07D 417/04
C07D 471/04
C07D 487/04
C07D 493/08
A61K 45/06
A61P 11/00

Abstract:

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

US Patent:

20180291006, Oct 11, 2018

Filed:

Oct 6, 2016

Appl. No.:

15/766667

Inventors:

- Cambridge MA, US
Cecilia M. Bastos - South Grafton MA, US
Daniel Parks - Pepperell MA, US
David Kombo - Lexington MA, US

International Classification:

C07D 405/04
C07D 487/04
C07D 493/08
C07D 471/04
C07D 417/04
C07D 413/04
C07D 413/14
C07D 409/14
C07D 409/04
C07D 405/14
C07D 401/04
A61P 11/00

Abstract:

The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.